|
|
|
|
Telaprevir Coinfection Study Open - Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2
This study is currently recruiting participants.Verified by Vertex Pharmaceuticals Incorporated, March 2010 Purpose The purpose of this study is to determine whether the combination of telaprevir, peginterferon alfa-2a, and ribavirin is safe and effective in...
|
|
|
Abacavir (Ziagen) Does Not Compromise Effectiveness of Hepatitis C Treatment, but Zidovudine (Retrovir) May Re
The effect of accompanying antiretroviral drugs on virological response to hepatitis C therapy using remains uncertain, given that prior studies have produced conflicting results.Like ribavirin, zidovudine can cause anemia, which may increase the risk of...
|
|
|
Global Communications Leader Porter Novelli Welcomes Stephanie Koze
NEW YORK, Feb.16 /PRNewswire/ -- Global public relations leader Porter Novelli announced today that Stephanie Koze has joined the agency as executive vice president and will manage its Shire Pharmaceutical Group business. Koze offers more than 20 years'...
|
|
|
Global Communications Leader Porter Novelli Welcomes Stephanie Koze
NEW YORK, Feb.16 /PRNewswire/ -- Global public relations leader Porter Novelli announced today that Stephanie Koze has joined the agency as executive vice president and will manage its Shire Pharmaceutical Group business. Koze offers more than 20 years'...
|
|
|
Global Communications Leader Porter Novelli Welcomes Stephanie Koze
Global public relations leader Porter Novelli announced today that Stephanie Koze has joined the agency as executive vice president and will manage its Shire Pharmaceutical Group business.Koze offers more than 20 years' experience overseeing U.S. and...
|
|
|
Global Communications Leader Porter Novelli Welcomes Stephanie Koze
Health Care Communications Veteran Joins Agency as Executive Vice President PR Newswire NEW YORK, Feb.16 NEW YORK, Feb. 16 /PRNewswire/ -- Global public relations leader Porter Novelli announced today that Stephanie Koze has joined the agency as executive...
|
|
|
Global Communications Leader Porter Novelli Welcomes Stephanie Koze
Health Care Communications Veteran Joins Agency as Executive Vice President PR Newswire NEW YORK, Feb.16 NEW YORK, Feb. 16 /PRNewswire/ -- Global public relations leader Porter Novelli announced today that Stephanie Koze has joined the agency as executive...
|
|
|
Global Communications Leader Porter Novelli Welcomes Stephanie Koze
Health Care Communications Veteran Joins Agency as Executive Vice President PR Newswire NEW YORK, Feb.16 NEW YORK, Feb. 16 /PRNewswire/ -- Global public relations leader Porter Novelli announced today that Stephanie Koze has joined the agency as executive...
|
|
|
Global Communications Leader Porter Novelli Welcomes Stephanie Koze
See more news releases in: Advertising, Agency Roster, Personnel Announcements Health Care Communications Veteran Joins Agency as Executive Vice President NEW YORK, Feb.16 /PRNewswire/ -- Global public relations leader Porter Novelli announced today that...
|
|
|
Recently released market study: Stakeholder Insight: Hepatitis B & C in Asia - China, South
China, Taiwan, South Korea and Turkey represent highly endemic areas for viral Hepatitis.For this report, 180 high-prescribing physicians where surveyed in these countries, providing a breakdown of numbers of treated patients and the most frequently...
|
|
|
Is One Type of Pegylated Interferon More Effective for Treating Chronic Hepatitis C?
is standard therapy for chronic hepatitis C, but there has not been consensus about the relative benefits of Pegasys (Roche/Genentech) and PegInton (Schering-Plough).Past research has produced conflicting findings, and data have not always been...
|
|
|
Human Genome calls hepatitis drug sleeper product
Human Genome Sciences Inc is awaiting a US approval decision later this year for Zalbin, an interferon that would compete with Roche Holding AGs big-selling Pegasys and Merck & Cos Inc Pegintron.The two current leading interferons are taken...
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial of CTS-1027 in Combination With Pegylated Interferon
SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients.
|
|
|
Human Genome calls hepatitis drug sleeper product
* Zalbin may take big market share from top interferons * Less-frequent dosing could give Zalbin edge * Annual $2 bln interferon market to grow with Zalbin * Could launch both Zalbin, Benlysta this year NEW YORK, Feb 9 (Reuters) - As Human Genome Sciences Inc...
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavir
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus HCV 2010 FEB 8 - (NewsRx.com) Conatus Pharmaceuticals Inc.announced the initiation of a Phase II clinical...
|
|
|
Research and Markets: Stakeholder Insight: Hepatitis B & C in Asia - China, South Korea, Taiwan and Turkey Includes Results of Surveys of 180 High-Prescribing Physicians
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/65d3a4/stakeholder_insigh) has announced the addition of the "Stakeholder Insight: Hepatitis B & C in Asia - China, South Korea, Taiwan and Turkey" report to their...
|
|
|
Research and Markets: Stakeholder Insight: Hepatitis B & C in Asia - China, South Korea, Taiwan and Turkey Includes Results of Surveys of 180 High-Prescribing Physicians
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/65d3a4/stakeholder_insigh) has announced the addition of the "Stakeholder Insight: Hepatitis B & C in Asia - China, South Korea, Taiwan and Turkey" report to their...
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
See more news releases in: Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Clinical Trials & Medical Discoveries SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical...
|
|
|
Pharmasset Initiates Phase 2a Trial with PSI-7977, a Chirally Pure Isomer of PSI-7851
PRINCETON, N.J., Jan.21 /PRNewswire-FirstCall/ -- Pharmasset, Inc. ( NASDAQ:VRUS) today announces the initiation of a 28-day Phase 2a study with PSI-7977, a chirally pure isomer form of PSI-7851, a nucleotide analog polymerase inhibitor in development for...
|
|
|
Pharmasset Initiates Phase 2a Trial with PSI-7977, a Chirally Pure Isomer of PSI-7851
PRINCETON, N.J., Jan.21 /PRNewswire-FirstCall/ -- Pharmasset, Inc. today announces the initiation of a 28-day Phase 2a study with PSI-7977, a chirally pure isomer form of PSI-7851, a nucleotide analog polymerase inhibitor in development for the treatment...
|
|
|
A Larger Proportion of Hepatitis C Non-Responder Patients Will Be Treated with Telaprevir Than Boceprevir
The Triple Therapy Combination of Telaprevir, Pegasys and Ribavirin Will Become the New Decision Resources Clinical Gold Standard for Hepatitis C Treatment Non-Responders in 2013 WALTHAM, Mass., Jan.19 /PRNewswire/ -- Decision Resources, one of the...
|
|
|
Stakeholder Insight: Hepatitis B & C In Asia - China, South Korea, Taiwan And Turkey - New Report Published
New report provides detailed analysis of the Healthcare and Medical market Published on January 14, 2010by Press Office(Companiesandmarkets.com and OfficialWire)LONDON, ENGLAND IntroductionChina, Taiwan, South Korea and Turkey represent highly endemic areas for...
|
|
|
Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 28th Annual J.P. Morgan Healthcare
{'s' : 'nktr','k' : 'c10,l10,p20,t10','o' : '','j' : ''} SAN CARLOS, Calif., Jan.6 /PRNewswire-FirstCall/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 28th Annual J.P...
|
